jRCT2031220356进行中（未招募）不适用
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 5
- 主要终点
- Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and Average of Week 15 through Week 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 0age 1month old over 至 No limit（—）
- 性别
- All
入选标准
- •The participant is Japanese male or female with a body weight >=3.0 kg and who is >=1 month of age at the time of informed consent.
- •The participant has a cholestasis as manifested by total serum bile acid (sBA) >=3^ upper limit of the normal range (ULN) (applies to the primary cohort only).
- •The participant has an average morning ItchRO (Obs) score >=1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2). Since it is difficult to evaluate pruritus in infants, participants <12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.
- •The caregiver has completed at least 21 valid* morning ItchRO (Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2) (*valid=completed and not answered as "I don't know"; the maximum allowed invalidreports=7, no more than 2 invalid reports during the last 7 days before the baseline visit [Week 0/Visit 2]).
- •The participant has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) based on:
- •Chronic cholestasis as manifested by persistent (>6 months*) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease (* =<6 months is acceptable for participants <12 months of age).
- •For Primary cohort:
- •a) The participant has a genetic testing result consistent with disease-causing variation in ABCB11 (PFIC2), based on a genotyping.
- •For Supplemental cohort:
- •a) The participant has a genetic testing results consistent with disease causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or tight junction protein 2 gene (TJP2) (PFIC4), based on a genotyping.
- •b) The participant has a PFIC phenotype without a known mutation or with another known mutation not described above.
- •c) The PFIC participant has internal or external biliary diversion surgery history, and the internal or external biliary diversion surgery was reversed.
- •The participant (whenever possible) and caregiver are able to be contacted by phone for scheduled remote visits (participant contacts [phone calls]).
- •Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
- •The same caregiver should be contacted during this study. The ItchRO (Obs) should be completed by the same caregiver for consistency during this study, even if the participant is an adult (over 18 years old).
排除标准
- •The diagnosed with PFIC2 due to ABCB11 mutation that predicts complete absence of BSEP function due to the type of ABCB11 mutation (t-PFIC2), based on a genotyping (applies to the primary cohort only).
- •The participant has a diagnosis of benign recurrent intrahepatic cholestasis indicated by a history of intermittent cholestasis with no disease progression.
- •The participant has a current or recent history (<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.
- •The participant has a previous history of surgical interruption of the enterohepatic circulation (applies to the primary cohort only).
- •The participant with chronic diarrhea requiring intravenous (IV) fluid or nutritional intervention and/or its sequelae at screening or during the 6 months prior to screening.
- •The participant has a history of liver transplant or currently requires imminent liver transplant.
- •The participant with decompensated cirrhosis (international normalized ratio [INR] >1.5, and/or albumin <30 g/L, history, or presence of clinically significant ascites, and/or variceal hemorrhage, and/or encephalopathy).
- •The participant has an alanine aminotransferase (ALT) or total serum bilirubin (TSB) level >15^ ULN at screening.
- •The participant has other liver disease.
- •The participant has any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease), per investigator discretion.
- •The participant has a possible malignant liver mass in imaging, including screening ultrasound.
- •The participant has received bile acid, lipid binding resins or ileal bile acid transporter (IBAT) inhibitors within 28 days prior to screening and throughout the trial.
- •The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.
结局指标
主要结局
Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and Average of Week 15 through Week 26
时间窗: Baseline to Week 15 through Week 26
The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Average baseline morning ItchRO (Obs) scores were calculated as sum of the morning scores divided by number of morning scores for the 4-week (28 days) time periods (that is [i.e.], Day -28 to Day -1). Average morning ItchRO (Obs) scores Week 15 through Week 26 were calculated as the sum of the morning scores divided by the number of morning scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
次要结局
- Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and Average of Week 15 through Week 26(Baseline to Week 15 through Week 26)
- Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26(Baseline to Week 26)
- Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline through Week 26(Baseline through Week 26)
- Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 through Week 26(Baseline to Week 15 through Week 26)
研究者
相似试验
招募中
不适用
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia ConditionsjRCT2031230135Takeda Pharmaceutical Company Limited500
未知
3 期
An open-label study of TAK-536 in patients with grade III hypertensioHypertensionJPRN-jRCT2080220836Takeda Pharmaceutical Company Limited
进行中（未招募）
1 期
TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRelapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 20.0 Level: HLT Classification code 10012819 Term: Diffuse large B-cell lymphomas System Organ Class: 100000004851EUCTR2016-003716-12-ESMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited82
进行中（未招募）
1 期
TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRelapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2016-003716-12-DEMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited122
进行中（未招募）
1 期
TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRelapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2016-003716-12-GBMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited122